Specimen Collection Cards Market Growth Accelerates with Rising Adoption in Diagnostics, Says Persistence Market Research

The global specimen collection cards market has witnessed substantial growth over the years, with projections indicating that its market size will reach USD 671.2 million by 2032, up from USD 477.0 million in 2025. This growth is expected to follow a CAGR of 5.0% from 2025 to 2032. Specimen collection cards are used in a variety of applications, from genomics and diagnostics to forensic science. These cards have become crucial tools in healthcare, enabling the collection, preservation, and transportation of biological samples, especially in remote or field-based settings where conventional sample collection methods are not feasible.

The increasing demand for decentralized diagnostics and remote sample collection, along with the rise in genetic testing, particularly in at-home genetic kits, is one of the driving forces behind the growth of this market. Additionally, advancements in specimen collection card technologies, particularly those designed to stabilize DNA, RNA, and small molecules, are fueling their adoption in clinical and research environments.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35329

Market Statistics, Key Growth Drivers, and Leading Segments

As per Persistence Market Research, North America is expected to remain the leading geographical region in the specimen collection cards market, contributing an estimated 35.4% market share by 2025. The U.S. is driving this growth through significant investments in newborn screening programs and decentralized diagnostics. The surge in government funding, particularly for infectious disease surveillance and forensics, is also contributing to the region's dominance. Blood samples, specifically, are set to hold a market share of around 88.4% in 2025. This is due to their ease of collection, ability to be stored without refrigeration, and the accuracy of quantitative analysis they provide for hormones, metabolites, and drugs.

Key Highlights from the Report

• The market size of the specimen collection cards is projected to reach USD 671.2 million by 2032.
• Blood samples are expected to dominate with an estimated 88.4% market share by 2025.
• Whatman 903 is forecasted to hold 41.7% of the market share in 2025.
• The adoption of specimen collection cards in telehealth and mail-in diagnostics is rapidly increasing.
• North America is expected to lead the market, contributing 35.4% of the global share by 2025.
• The integration of specimen collection cards in forensic toxicology and public health programs is on the rise.

Market Segmentation
By Product Type

The specimen collection cards market is segmented into various types, with Whatman 903 and FTA being the most prominent. Whatman 903, a cellulose-based filter paper, holds a significant share of the market due to its ability to provide consistent analyte absorption and high recovery rates. It is particularly popular in clinical settings, where precise sample handling and storage are essential. FTA cards, on the other hand, are widely used for preserving nucleic acids such as DNA and RNA. These cards offer robust preservation capabilities, particularly in field-based applications where samples need to be stored without refrigeration.

By Specimen Type

The market is also segmented based on the type of biological specimen collected, with blood samples being the dominant segment. Blood samples are used for a wide range of applications, including hormone analysis, metabolic disease diagnosis, and pharmacokinetics. Saliva, urine, and buccal cells are also important specimen types, but blood remains the most prevalent due to its ability to provide a comprehensive analysis from a single dried sample. Saliva collection, however, is expected to grow at a steady rate as it is non-invasive, easily collected, and ideal for genomic studies.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/specimen-collection-cards-market.asp

Regional Insights
North America

North America is expected to be the dominant region in the specimen collection cards market, driven by high adoption rates in the U.S. The country's robust healthcare infrastructure and its focus on newborn screening and forensic applications are key factors contributing to this dominance. For example, DBS cards are currently used for newborn screening in all 50 U.S. states, screening millions of infants each year for metabolic and genetic conditions.

Middle East and Africa

In the Middle East and Africa, the market for specimen collection cards is growing due to the expansion of newborn screening programs. Countries like Saudi Arabia are increasingly adopting DBS cards for metabolic screening of newborns. This trend is expected to continue, with more nations in the region recognizing the value of dried blood spot testing for early disease diagnosis. In sub-Saharan Africa, the use of DBS cards for HIV monitoring is increasing, particularly in resource-limited settings.

Market Drivers

Several factors are contributing to the rapid growth of the specimen collection cards market. One of the key drivers is the rising demand for genetic testing and field research. As the need for decentralized healthcare models increases, specimen collection cards are gaining attention for their ability to store samples at ambient temperatures without requiring refrigeration. This capability is highly beneficial in rural or under-resourced regions where cold chain logistics are often challenging.

The increasing popularity of at-home genetic testing is also contributing to market growth. Companies like 23andMe and Myriad Genetics are utilizing specimen collection cards to enable customers to collect samples, such as saliva or buccal cells, at home and send them back for analysis. This not only facilitates remote sampling but also reduces costs associated with traditional sample collection methods.

Market Restraints

Despite the growing demand for specimen collection cards, certain restraints could hinder market expansion. One of the primary challenges is the hematocrit bias that affects blood sample collection on DBS cards. Variations in hematocrit levels can lead to inaccurate analyte measurements, particularly for quantitative assays in drug monitoring and hormone testing. This could limit the adoption of DBS cards in regulated diagnostic settings that require high precision.

Moreover, some healthcare professionals remain hesitant to adopt specimen collection cards due to concerns about the uniformity of sample spreading and the accuracy of results. In certain clinical applications, these issues could undermine the reliability of DBS cards for critical diagnostic tests.

Market Opportunities

A significant opportunity for the specimen collection cards market lies in forensic toxicology testing. As law enforcement agencies and public health bodies face increasing challenges related to drug abuse, the demand for reliable, non-invasive specimen collection methods is growing. DBS cards provide a tamper-evident, easy-to-store solution for collecting blood, urine, and saliva samples for toxicological analysis, making them ideal for postmortem investigations and workplace drug testing.

Another promising opportunity lies in the expansion of bio-banking and longitudinal studies. As the need for long-term sample storage grows, specimen collection cards, especially FTA cards, are becoming invaluable tools for researchers collecting DNA, RNA, and other biomaterials for genetic studies.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35329

Reasons to Buy the Report

• Gain insights into the growth trajectory and key drivers of the specimen collection cards market.
• Understand regional trends and the factors influencing market dynamics in different geographical regions.
• Explore segmentation analysis based on product type, specimen type, and end-use applications.
• Stay updated on recent technological advancements and key developments in the specimen collection cards industry.
• Identify the leading market players and learn about their strategies, including R&D and market expansion plans.

Frequently Asked Questions (FAQs)

• How big is the specimen collection cards market?
• Who are the key players in the global specimen collection cards market?
• What is the projected growth rate of the specimen collection cards market?
• What is the market forecast for specimen collection cards by 2032?
• Which region is estimated to dominate the specimen collection cards market through the forecast period?

Company Insights
Key Players

• QIAGEN N.V.
• PerkinElmer Inc.
• Danaher Corporation
• DBS System SA
• GenTegra LLC
• CENTOGENE N.V.
• Eastern Business Forms, Inc.
• Ahlstrom
• ARCHIMED Life Science GmbH
• FortiusBio

Recent Developments

In November 2024, Capitainer launched CapitainerSEP10, a new sampling card designed for collecting separated blood samples from a finger prick without the need for a centrifuge.

In February 2024, researchers at Baylor College of Medicine and the Medical University of South Carolina announced their work on Dried Fecal Spot (DFS) cards, aimed at enhancing fecal sample preservation for analysis.

Conclusion

The specimen collection cards market is poised for robust growth over the next few years, driven by advancements in genomics, diagnostics, and the increasing demand for decentralized healthcare solutions. With a projected market size of USD 671.2 million by 2032 and a CAGR of 5.0%, the industry is set to benefit from the rise in at-home genetic testing, remote sampling, and the need for reliable, cost-effective specimen preservation methods. Key players, such as QIAGEN, PerkinElmer, and Danaher Corporation, are actively enhancing product offerings and investing in innovative technologies to meet the growing demand for high-quality specimen collection cards.

North America is likely to remain the leading market due to its well-established healthcare infrastructure and ongoing investments in newborn screening and forensic applications. Additionally, regions like the Middle East and Africa, and Asia Pacific, are witnessing rapid adoption of specimen collection cards, particularly for newborn screening, infectious disease monitoring, and forensic toxicology applications.

Read More Related Reports:

Neurological Biomarkers Market https://www.persistencemarketresearch.com/market-research/neurological-biomarkers-market.asp
Hospice Services Market https://www.persistencemarketresearch.com/market-research/hospice-services-market.asp
Hygiene Monitoring System Market https://www.persistencemarketresearch.com/market-research/hygiene-monitoring-system-market.asp
Medication Dispenser Market https://www.persistencemarketresearch.com/market-research/medication-dispenser-market.asp
Fc Fusion Protein Market https://www.persistencemarketresearch.com/market-research/fc-fusion-protein-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.